Print
Email
Print Edition StoriesTuesday, December 8, 2009
EnVivo drug study again prompts signs of Alzheimer's reversal
By Mass High Tech staff
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
MHT's Marc Songini: Technology to keep seniors healthy
A new study has returned promising results for modifying and potentially reducing the effects of Alzheimer’s disease — supporting previous test results from July that returned the same behavior reversal qualities.
EnVivo Pharmaceuticals Inc., a drug developer in Watertown, has found in a study of its gamma-secretase modulator, EVP-0962, that it helped lead to a reduction of the peptide AB42 associated with Alzheimer’s disease.
The independent study was conducted with Amorflix Life Sciences Ltd., which supplied its A4 assay to determine an increase in AB42 for animals with Alzheimer’s disease.
Privately held EnVivo focuses on drug development related to central nervous system disorders, including Huntington’s disease, in addition to schizophrenia and Alzheimer’s disease. The company last received funding in the amount of $65 million from a fourth-round venture capital financing, led by Fidelity Biosciences. In April, the company announced that it had signed a licensing agreement for its schizophrenia and Alzheimer’s disease treatment, EVP-6124, with Mitsubishi Tanabe Pharma Corp. (MTPC).
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
